A marker associated with increased risk for severe liver disease in cystic fibrosis

Clinical Genetics

Volumn 77, Issue 5, 2010, Pages 434-435

  de Haan, W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; ENDOPLASMIC RETICULUM; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; LIVER DISEASE; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; PROTEIN DEPLETION; RISK ASSESSMENT;

EID: 77953078109     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01365_1.x     Document Type: Note

References (5)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009, 373:1891-1904.
2. Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2009, 25:272-278.
3. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008, 103:2136-2141.
4. Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3:16.
5. Frangolias DD, Ruan J, Wilcox PJ. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2003, 29:390-396.